SCHEMBL22801029

SCHEMBL22801029

CSc1ncccc1C(=O)Nc1nc(-c2cccc(Nc3ccc(C#N)cn3)c2)cs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.47
NPC1 O15118 6/20 0.47
RAB9A P51151 5/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
KMT2A Q03164 4/20 0.47
NFKB1 P19838 3/20 0.47
NFKB2 Q00653 3/20 0.47
RELA Q04206 3/20 0.47
MEN1 O00255 3/20 0.47
TP53 P04637 1/20 0.47
CASP3 P42574 1/20 0.47
GFER P55789 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
KDM4E B2RXH2 4/20 0.47
MAPK1 P28482 1/20 0.47
CFTR P13569 1/20 0.46
ALDH1A1 P00352 2/20 0.45
SLC2A1 P11166 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22801102 0.90 CFTR (0.51) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL22801045 0.90 CSNK2A2 (0.49) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL22801107 0.89 SLC2A1 (0.48) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL22801034 0.85 KDM4E (0.50) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL22801090 0.84 CSNK2A2 (0.54) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL22801077 0.84 MAPT (0.46) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL22822211 0.84 MAPT (0.54) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL22801071 0.83 KMT2A (0.46) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL22801133 0.81 LMNA (0.51) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL22801082 0.80 MAPT (0.49) MAPTNPC1RAB9ASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200399264-A1 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS NATIONAL INSTITUTES OF HEALTH 2020-12-24 US disclosed
US-20200399264-A1 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS NATIONAL INSTITUTES OF HEALTH 2020-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399264-A1 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS MAVS, ZC3HAV1, EIF2AK2 MAPT 347/4885NPC1 1860/4885RAB9A 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.